Neuro-Bio is now collaborating with Tino Rossi. Tino has over 40 years of experience in drug discovery and development having occupied roles of growing seniority and leadership in Medicinal Chemistry, Chemical Development and Preclinical Drug Discovery in...
Neuro-Bio welcomes Mark I. Butler as new COO Designate. Mark holds a Ph.D. in Pharmacology from the University of Bristol, where he completed a “bench-to-bedside” thesis focusing on the mechanisms of new antiplatelet agents. He has over ten years...
Neuro-Bio’s CEO, Susan Greenfield, has been invited in Vienna for the 8th EAN Congress, which is the forum for general neurology in Europe with all specialties of its field being represented with around 6000 participants. While clinical developments play an...
Neuro-Bio’s CEO, Susan Greenfield has kindly accepted to be member of the IAB of the upcoming 14th International Meeting on Cholinesterases and the 8th International Conference on Paraoxonases to be held in Bologna 18-21.09.2022. The multidisciplinary Conference...
The Barclays Scale Up UK Programme addresses the core challenges businesses, founders and their senior management teams face in scaling, by providing a bespoke, hands-on approach to help you accelerate your business’ growth. Neuro-Bio has decided to participate...
Following the new Government guidelines of lifting all the restrictions in place , Neuro-Bio takes responsibility to implement the following measures to protect staff members and visitors. Free Lateral Flow Test offered to visitors and staff members Weekly staff...
On Wednesday the 2nd of February, Neuro-Bio’s CEO, Susan Greenfield, attended the Hilary dinner at the St John’s college in Oxford. She was invited as a guest speaker and the title of her talk was: “Disruptive discoveries inspired by a basic...
Neuro-Bio welcomes Anton Shmelev as part of the team. Anton hopes to apply his experience in the areas of protein misfolding, receptor trafficking, as well as general protein science and molecular biology into the field of the Alzheimer’s research conducted at...
We are delighted to announce that our seminal paper A novel process driving Alzheimer’s validated in a mouse model: therapeutic potential’ has been accepted by the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical...
Great success for Neuro-bio’s CEO, Susan Greenfield at the Rosalind Franklin Institute on Thursday 27.01. She talked about the assets that the company is currently working on and had the chance to talk and meet the audience. The Neuro-bio’s team was there...
